巨子生物控股有限公司（股票代号：02367）于2026年1月6日发布翌日披露报表，披露当日公司在香港联合交易所回购40万股普通股。该批股份回购价格区间介乎每股33.84港元至34.48港元，合计涉资约1367万港元。公司确认上述股份将予注销，回购后其已发行股本仍维持在约10.70904亿股水平。
根据公告，回购所依据之购回授权于2025年6月13日获股东大会通过，其上限为1.070904亿股。截至公告日期，公司已累计回购600万股，占授权通过时已发行股本约0.5603%。公司强调，该回购行为符合上市规则及相关法律规定。
本次公告由执行董事兼联席公司秘书严鈺博签署。公司重申各项回购及后续程序均符合香港联合交易所有限公司的规定，且不存在任何重大变动或其他违规情形。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.